PMC10614030

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

In MarketScan data, women with HIV and non-dolutegravir antiretroviral exposure had significantly higher stillbirth risk compared to women without HIV, with an adjusted risk ratio of 2.10; no signific

Effect: decline; aRR 2.10; CI: 95% CI 1.24-3.55

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54

Women with HIV and periconceptional dolutegravir exposure had significantly higher risk of pregnancy loss compared to women without HIV, with adjusted risk ratios of 1.73 in MarketScan and 1.41 in Med

Effect: decline; aRR 1.41; CI: 95% CI 1.30-1.54